Ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate;hydron;chloride;hydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate;hydron;chloride;hydrate
• 化学式: C22H28BrClN2O4S
• 分子量: 531.9
• InChiKey: PLWQHPWNKPKQJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.77
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  81
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate;hydron;chloride;hydrate 、 、 、 、 Stearic acid calcium salt 以0.10 g of stearic acid is produced的产率得到硬脂酸
  参考文献：
  名称：

  Pharmaceutical composition with anti-diabetic action

  摘要：

  本发明涉及医学，特别是寻找和开发治疗胰岛素糖尿病的新型药物。该发明基于开发更有效和毒性更小的药物，这些药物基于吲哚衍生物，具有抗糖尿病、降脂、降血糖、降胆固醇活性和改善胰岛素抵抗作用，并且其结构与传统使用的化合物不同。发明的吲哚衍生物也具有低毒性和易耐受性。

  公开号：

  US08247407B2

文献信息

• PHARMACEUTICAL COMPOSITION WITH ANTI-DIABETIC ACTION
  申请人：Demin Alexander Victorovich

  公开号：US20100168092A1

  公开（公告）日：2010-07-01

  The invention relates to medicine, in particular to searching and developing novel medicinal agent for treating pancreatic diabetes. The invention is based on the development of more effective and less toxic medicinal agents based on indole derivatives which exhibit antidiabetic, hypolipidemic, hypoglycemic, hypocholesterolemic activity and insulin resistance-improving actions and the structure of which differs from the structure of traditionally used compounds. The inventive indole derivatives are also low-toxic and easily tolerated.

  本发明涉及医学领域，特别是寻找和开发治疗胰岛素糖尿病的新型药物。本发明基于开发基于吲哚衍生物的更有效和毒性更小的药物，这些药物表现出抗糖尿病，降脂，降血糖，降胆固醇活性和改善胰岛素抵抗作用，其结构与传统使用的化合物不同。本发明的吲哚衍生物也具有低毒性和易耐受性。
• 5-HYDROXYINDOLE-3-CARBOXYLATES DERIVATIVES AND THEIR USE
  申请人：Shenyang Pharmaceutical University

  公开号：EP1731506A1

  公开（公告）日：2006-12-13

  The present invention relates to 5-hydroxy-indole-3-carboxylate derivatives of formula I , or racemic mixture or optical isomers or pharmaceutically acceptable salts and/or hydrates thereof, wherein: substitutents R1, R2, Z, X and Y are as defined in the description. The compounds of formula I can be useful for preparation of medicament for treatment and/or prophylaxis of virus infections, especially for preparation of medicament for anti-HBV (Hepatitis B virus) and anti-HIV (Human immunodeficiency virus).

  本发明涉及式 I 的 5-羟基-吲哚-3-羧酸盐衍生物，或其外消旋混合物或光学异构体或药学上可接受的盐和/或水合物、 其中 取代基 R1、R2、Z、X 和 Y 如描述中所定义。式 I 化合物可用于制备治疗和/或预防病毒感染的药物，特别是用于制备抗 HBV（乙型肝炎病毒）和抗 HIV（人类免疫缺陷病毒）的药物。
• SULFUR-BASED BROAD SPECTRUM ANTIVIRALS
  申请人：Washington State University

  公开号：US20180271823A1

  公开（公告）日：2018-09-27

  Methods of using the formulations disclosed herein to treat or prevent a broad spectrum of enveloped viruses are provided. In particular, a method of treating or preventing a disease state caused by an enveloped type virus can include agents of a formula wherein R 1 , is selected from the group consisting of OH, OR 6 , NHR 6 , and NR 6 R 7 where R 6 and R 7 are selected from the group consisting of alkyl, aryl, methyl and heteroaryl; R 2 is selected from the groups consisting of OR 6 , acyl, alky, aryl, and sulfonyl; R 3 is selected from the group consisting of OR 6 alkyl, aryl, substituted aryl, and heteroaryl; R 4 and R 5 are independently selected from the groups consisting of hydrogen, methyl or alkyl, substituted alkyl, aryl, and substituted aryl; and whereby, administration of the compound allows for the treatment of enveloped viruses.
• METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20210283152A1

  公开（公告）日：2021-09-16

  Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.
• US5198552A
  申请人：——

  公开号：US5198552A

  公开（公告）日：1993-03-30